Abbasi, F. et. al. Results of a placebo-controlled study of the metabolic effects of the addition
of metformin to sulfonylurea-treated patients: Evidence for a central role of adipose tissue.
Diabetes Care, 1997; 20(12)1863-1869.
American Diabetes Association. Clinical Practice Recommendations 2000. Diabetes Care, 2000;
Vol.23, supp 1.
American Diabetes Association. Report of the expert committee on the diagnosis and classification of
diabetes mellitus. Diabetes Care, 1997; 20:1183-1197.
Antonucci T, Whitcomb R, McLain R, et. al. Impaired glucose tolerance is normalized by treatment with
the thiazolidinedione troglitazone. Diabetes Care, 1997;20:188-193.
Aviles-Santa L, Sinding J, & Raskin P. Effects of metformin in patients with poorly controlled, insulin-
treated type 2 diabetes mellitus. Ann Intern Med, 1999;131:182-188.
Bell PM. Clinical significance of insulin resistance. Diabet Med, 1996;13:504-509.
Berkowitz K, Peters R, Kjos SL, et. al. Effect of troglitazone on insulin sensitivity and pancreatic B-Cell
function in women at high risk for NIDDM. Diabetes, 1996;45:1572-1579.
Brewer, KW et. al. Slicing the pie: Correlating HbA1c values with average blood glucose values in a pie
chart form. Diabetes Care, 1998; 21(2)209-212.
Cefalu, WT, Parker, TB, & Johnson, CR. Validity of serum fructosamine as index of short-term
glycemic control in diabetic outpatients. Diabetes Care, 1988; 11(8)662-664.
Cerasi, E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible?
Diabetologia, 1995; 38:992-997.
Conniff, RF et. al.. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by Acarbose
in patients with NIDDM: A placebo-controlled dose-comparison study. Diabetes Care, 1995;
Dagogo-Jack, S & Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic
Interventions. Arch Intern Med, 1997;157:1802-1817.
Davidson, MB & Peters, AL. An overview of metformin in the treatment of type 2 diabetes mellitus.
American Journal of Med, 1997; 102:99-110.
DeFronzo, RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-
DeFronzo, RA & Goodman, AM and the Multicenter Metformin Study Group. Efficacy of metformin in
patients with non-insulin-dependent diabetes mellitus. NEJM, 1995; 333(9)541-549.
Després, J et. al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J
Med, 1996; 334:952-967.
Draeger, K et. al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent
glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm. Metab. Res.,
Dunn CJ & Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs, 1995;49:721-749.
Ferrannini, E. et. al. Insulin resistance, hyperinsulinemia, and blood pressure: Role of age and obesity.
Hypertension, 1997; 30:1144-1149.
Ferrannini, E. et. al. Insulin resistance and hypersecretion in obesity. J. Clin. Invest., 1997;
Fontbonne A, Charles MA, Juhan-Vague I, et. al. The effect of metformin on the metabolic abnormalities
associated with upper-body fat distribution. Diabetes Care, 1996;19:920-926.
Fonseca V, Rosenstock J, Patwardhan R, et. al. Effect of metformin and rosiglitazone combination
therapy in patients with type 2 diabetes mellitus. JAMA, 2000;283:1695-1702.
Garber AJ, Duncan TG, Goodman, AM, et. al. Efficacy of metformin in type II diabetse: results of a
double-blind, placebo-controlled, dose response trial. AM J Med, 1997;102:491-497.
Garber, AJ. Metformin therapy for type II diabetes mellitus. Pharmacy and Therapeutics, September
Ghazzi MN, Perez JE, Antonucci TK, et. al. Cardiac and glycemic benefits of troglitazone treatment in
NIDDM Diabetes, 1997;46:433-439.
Goldberg, RB et. al. A dose-response study of glimepiride in patients with NIDDM who have previously
received sulfonylurea agents. Diabetes Care, 1996; 19:849-856.
Garancini, M.P. et. al. Factors related to glycemic control in IDDM and insulin-treated NIDDM patients
in current practice: A comparison of care policies. Diabetes Care, 1997; 20(11) 1659-1663.
Goldstein, DE et. al. Tests of glycemia in diabetes. Diabetes Care, 1995; 18(6)896-909.
Granberry MC, Schneider EF, & Fonseca VA. The role of troglitazone in treating the insulin resistance
syndrome. Pharmacotherapy, 1998;18:973-987.
Haffner, SM & Miettinen, H. Insulin resistance implications for type II diabetes mellitus and coronary
heart disease. Am. J. Med., 1997; 103:152-162.
Haffner, SM et. al. Prospective analysis of the insulin resistance syndrome (Syndrome X). Diabetes,
Haller, H et. al. The role of hyperglycemia on hyperinsulinemia in the pathogenesis of diabetic
angiopathy. Clinical Nephrology, 1996; 46:246-255.
Harris, MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care, 1993, 16:642-652.
Inzucchi, SE et. al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes
mellitus. NEJM, 1998; 338(13)867-872.
Iwamoto, Y et. al. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly
controlled by diet therapy. Diabetes Care, 1996; 19:151-156.
Iwamoto, Y. et. al. Effect of combination therapy of troglitazone and sulphonylureas in patients with
type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic
Medicine, 1996; 13:365-370.
Jha RJ. Thiazolidinediones-the new insulin enhancers. Clin and Exper Hypertension, 1999;21(1&2):157-
Johnson MD, Campbell LK, & Campbell RK. Troglitazone: Review and assessment of its role in the
treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann
Johnson, JL, Wolf, SL, & Kabadi, UM. Efficacy of insulin and sulfonylurea combination therapy in
type II diabetes. Arch Intern Med, 1996; 156:259-264.
King, GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in
diabetes. Annals of Medicine, 1996; 28:427-432.
Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes,
Laakso, M. Insulin resistance and coronary heart disease. Current Opinion in Lipidology, 1996;
Laakso, M. How good a marker is insulin level for insulin resistance? American Journal of
Epidemiology, 1993; 137(9)959-965.
Laakso, M. et. al. Essential hypertension and insulin resistance in non-insulin dependent diabetes.
European Journal of Clinical Investigation, 1989; 19:518-526.
Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2
Diabetes. Diabetes Care, 1999;21(suppl 3):c41-c44.
Lettieri JT & Dain B. Effects of Beano on the tolerability and pharmacodynamics of Acarbose. Clin
Lithell, HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J
Hypertension, 1996; 9:150S-154S.
Mayer-Davis, EJ et. al. Intensity and amount of physical activity in relation to insulin sensitivity: The
insulin resistance atherosclerosis study. JAMA, 1998; 279(9)669-674.
Misbin, RI et. al. Lactic acidosis in patients with diabetes treated with metformin. NEJM, 1998;
Nagi, DK & Yudkin, JS. Effects of metformin on insulin resistance, risk factors for cardiovascular
disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care, 1993; 16(4)621-629.
Nolan, JJ et. al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with
troglitazone. NEJM, 1994; 331:1188-1193.
Nozue T, Michishita I, Minagawa F, et. al. Troglitazone directly increases HDL cholseterol levels.
Diabetes Care, 1999;22:355-356.
Ogihara T, Rakugi H, Ikegami H, et. al. Enhancement of insulin sensitivigty by troglitazone lowers blood
pressure in diabetic hypertensives. Am J Hypertens, 1995;8:316-320.
Reaven GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition.
Ann Rev Med, 1993;44:121-131.
Reaven, GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes, 1988;
Rosenstock J, Brown A, Fischer J, et. al. Efficacy and safety of acarbose in metformin-treated patients
with type 2 diabetes. Diabetes Care, 1998;21:2050-2055.
Saltiel, AR & Olefsky, JM. Thiazolidinediones in the treatment of insulin resistance and type II
diabetes. Diabetes, 1996; 45:1661-1669.
Schwartz, S. et. al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus.
NEJM, 1998; 338(13)861-866.
Sprietsma, JE & Schuitemaker, GE. Diabetes can be prevented by reducing insulin production.
Medical Hypotheses, 1994; 42:15-23.
Stout, RW. Insulin and atheroma: 20-yr perspective. Diabetes Care, 1990; 13:631-654.
Stumvoll, M et. al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
NEJM, 1995; 333:550-554.
Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related
disorders. Clin and Exper Hypertension, 1999;21(1&2):121-126.
Sulkin, T. et. al. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care,
Turner RC, Cull CA, Frighi V, et. al. Glycemic control with diet, sulfonylurea, metformin, or insulin in
patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS
49). JAMA, 1999;281:2005-2012.
UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). The Lancet, 1998; 352:837-853.
UK Prospective Diabetes Study Group (UKPDS). Effect of intensive blood-glucose control with
metformin on omplications in overweight patients with type 2 diabetes (UKPDS 34). The
Lancet, 1998; 352:854-865.
Whitcomb, WR & Saltiel, AR. Thiazolidinediones. Exp. Opin. Invest. Drugs, 1995; 4:1299-1309.
Wiman, B. Plamsinogen Activator Inhibitor 1 (PAI-1) in plasma: It's role in thrombotic disease.
Thrombosis and Haemostasis, 1995; 74(1)71-76.
Yarnell, JWG et. al. Insulin in ischaemic heart disease: are associations explained by Triglyceride
concentrations? The Caerphilly prospective study. British Heart Journal, 1994; 71:293-296.
Yki-Jarvinen H, Ryysy L, Nikkila K, et. al. Comparison of bedtime insulin regimens in patients with type
2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med, 1999;130:389-396.
Yudkin, JS. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart
disease. Annals of Medicine, 1996; 28:433-438.